TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06155032

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular therapy
Description: Patients in this group will receive best medical management plus EVT including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty or stenting.~In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy or aspiration thrombectomy will be recommended as the primary treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Description: Patients in this group will receive best medical management plus EVT including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty or stenting.~In the procedure, the methods including mechanical thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, angioplasty and stenting can be used according to the local interventionalists' choice. Mechanical thrombectomy or aspiration thrombectomy will be recommended as the primary treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best medical management
Description: All the patients enrolled received standard guideline-directed medical therapy including: monitor vital signs, management of blood pressure, glucose and lipids, antithrombotic (antiplatelet or anticoagulant therapy determined by treating physician) therapy if appropriate
Study: NCT04674254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Injection
Description: Bevacizumab will be intravitreally injected every 4 weeks through 12 weeks then pro re nata thereafter for 12 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Targeted retinal photocoagulation
Description: Targeted retinal photocoagulation will be administered to nonperfused areas detected on fundus fluorescein angiography at baseline and repeated every 3 months as needed for 12 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard pan-retinal photocoagulation
Description: Standard pan-retinal photocoagulation will be applied to perfused and nonperfused areas of the retinal periphery at baseline and every 3 months as needed for 12 months.
Study: NCT05258409

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Media Advocacy (MA)
Description: MA content generally centers on acknowledging and discussing the role the media has on shaping body image ideals. Session 1: In session 1, similar to MTM, the primary activities will include: (1) describing the ideal body for men in our culture, (2) discussing how the media impacts this ideal, with a particular focus on advertising. Following this, participants will (3) watch a video on how the media influences body image among men, and the consequences of internalizing these messages. Session 2: In session 2, content will continue by further discussion of the video showed in session 1, with participants sharing their reactions. Next, the group discusses the attainability of the ideal as well as discusses other forms of media (e.g., social media) and how it impacts body image.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: More than Muscles (MTM)
Description: In session 1, the primary activities are: 1) define the ideal body type for men in our culture, 2) discuss the origin and perpetration of the ideal, 3) brainstorm the costs of pursuing the ideal, 4) participate in a verbal challenge during which participants counter the ideal message, and (5) are asked to complete three homework assignments (i.e., a letter to an adolescent boy, a behavioral challenge, and a mirror exposure assignment). In session 2, the primary activities are: 1) reviewing homework, 2) engage in role-plays to counter/discourage pursuit of the ideal, 3) discuss ways to challenge and avoid negative body talk statements, 4) list ways to resist the pressure to pursue this ideal both individually and as a group within the larger community (i.e., body activism), 5) discuss barriers to body activism and strategies to overcome those barriers, and 6) individually select an exit exercise to continue to actively challenge the appearance ideal.
Study: NCT06168747

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Passive Joint Mobilization
Description: Wrist mediolateral glide, 1st MCP joint anteroposterior glide, CMC joint mediolateral, and anteroposterior glide were applied to the individuals. Applications were made 6 times with 3 repetitions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Joint Mobilization
Description: Wrist mediolateral glide, 1st MCP joint anteroposterior glide, CMC joint mediolateral, and anteroposterior glide were applied to the individuals. Applications were made 6 times with 3 repetitions
Study: NCT05456854

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hyperglycemic Clamp
Description: Administration of a hyperglycemic clamp

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Hyperglycemic Clamp
Description: Administration of a hyperglycemic clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kisspeptin-10
Description: Administration of kisspeptin-10 \* 16 hr

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo \*16 hr
Study: NCT05827588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AWAK PD
Description: Daily 7- or 9-hour therapy (with or without a last fill) that is a form of automated peritoneal dialysis being done by subjects who are already on daily PD therapy
Study: NCT05464121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: • Blended treatment for AjD combining a self-applied Internet-based program (TAO) with face-to-face sessions via videoconference.
Description: The self-applied Internet-based program called TAO is accessible online from the platform https://psicologiaytecnologia.labpsitec.es. It is organised into 7 sequential modules of approximately 60 minutes. The patient will do a treatment module every 10-12 days, plus an individual session via videoconference with a therapist (approximately 20-30 minutes long). During these sessions, the therapist will explain the main contents of each module, resolve doubts and motivate the patient to continue with the therapy. It takes about 12 weeks to complete the intervention.~TAO is the optimised version of the original intervention protocol for AjD developed by Botella et al. by Botella et al. (2008) and includes the following therapeutic components: psychoeducation, emotion regulation techniques, exposure, problem-solving techniques, Mindfulness, acceptance and elaboration of the stressful event, positive psychology strategies and relapse prevention.
Study: NCT06572943

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity physical activity
Description: Moderate intensity exercise of 30 minutes for at least 4-5 times per week (if not daily).
Study: NCT06154174

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C-RUTF (Ready-to-Use Therapeutic Food with added choline)
Description: Choline added to peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: S-RUTF (Ready-to-Use Therapeutic Food without added choline)
Description: Standard peanut paste-based ready-to-use therapeutic food meeting Codex Alimentarius specifications

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Oral amoxicillin tablets twice per day for 7 days dosed based on weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Oral amoxicillin tablets twice per day for 7 days dosed based on weight
Study: NCT04978077

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal (high fat = Nutricia Calogen®, or high carbohydrate = Nutricia preOp®)
Description: After a night fast participants will drink the test meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test meal (high fat = Nutricia Calogen®, or high carbohydrate = Nutricia preOp®)
Description: After a night fast participants will drink the test meal
Study: NCT06150469

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Blend of ginger and lemon essential oils, Neutral oil
Description: Patients will be given aromasticks to inhale the blend of essential oils.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Blend of ginger and lemon essential oils, Neutral oil
Description: Patients will be given aromasticks to inhale the blend of essential oils.
Study: NCT06640881

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ablative single-dose PBI
Description: ablative single-dose PBI followed by BCS after three weeks At baseline (prior to RT) and prior to BCS, toxicity, PROMS and cosmetic outcome will be assessed. Additionally, a preoperative MRI will be performed three weeks following RT to evaluate the acute tumor response.
Study: NCT06364176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Treatment with losartan through week 12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with placebo through week 12
Study: NCT05807425

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polidocanol foam sclerotherapy
Description: The preparation of the foam is done according to the Tessari's technique using 2 disposable 20ml syringe, a three-way tap and a 10cm reusable extender adapted to intravenous needle. The sclerosant is applied according to the Blanchard's technique through a disposable transparent anoscope with the patient in jack-knife (knee-chest) position. In each session treatment can be performed on more than one hemorrhoidal cushion. The maximum dose per treatment session is 20ml (mixture of 4ml of polidocanol 3% with 16ml of air).
Study: NCT05708300

Intervention type: DRUG
Intervention: Mepolizumab 100 MG [Nucala]
Description: subcutaneous injection once a month

Intervention type: DRUG
Intervention: Mepolizumab 100 MG [Nucala]
Description: subcutaneous injection once a month
Study: NCT06007105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SUCCEED Community-Based Intervention
Description: The main components of the intervention are peer support, case management and livelihoods activities, delivered by a peer support worker and a community support worker. The peer support worker has lived experience of psychosis and draws on a variety of manualised tools and techniques adapted from previous studies. The community support worker mobilises families and communities to activate resources in support of participants (e.g., education and employment, social and recreational activities), drawing on established models of mental health case management and community-based inclusive development. The peer support worker and community support worker also run self-help groups for people with lived experience and their family members, respectively. Self-help group meetings are also used as an opportunity for group livelihoods activities taking an ABCD (asset-based community development approach.
Study: NCT04761692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full VEPMP Intervention
Description: Delivery of intrapersonal/interpersonal (i.e., motivational interviewing, vaccine educators, personal testimony, etc.), AND organizational (i.e., church-based sponsored events, seminars, web/online activities, bulletin inserts, etc.)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial VEPMP Intervention
Description: Delivery of iAND organizational (i.e., church-based sponsored events, seminars, web/online activities, bulletin inserts, etc.)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed VEPMP Intervention
Description: Delayed implementation of delivery of intrapersonal/interpersonal AND organizational after 1 year of study start
Study: NCT04678765

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided distal peripheral nerve block
Description: To localize the median nerve, the ultrasound transducer will be placed in a transverse orientation proximally to the wrist cease at mid-forearm level, with a slight tilt distally towards the hand. An in-plane ultrasound-guided medial-to-lateral puncture will be made and 3ml of 2% lidocaine was injected within the fascia that envelopes the median nerve.~To perform the ulnar block, an ultrasound transducer will be placed in a transverse orientation over the ulnar side of the distal forearm. An in-plane ultrasound-guided medial-to-lateral or proximal-to distal puncture will be made and 3 ml of 2% lidocaine will be infiltrated into the fascial plane to block the ulnar nerve. Finally, we will apply a circumferential subcutaneous infiltration of 4 ml 2% lidocaine at the radial side of the wrist, 2cm proximal to the styloid process of the radius to block the terminal sensory branches of the radial, musculocutaneous, and medial antebrachial cutaneous nerves that may reach the palmar crease.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided quadruple-injection axillary nerve block
Description: The US probe will be applied in the axilla to obtain a short-axis view of the axillary artery. The following 4 nerves will be identified as hyperechoic structures: the median, ulnar, and radial nerve surrounding the axillary artery and the musculocutaneous nerve in the fascial layers between the biceps and coracobrachialis muscles.~A total volume of 20 mL lidocaine 2% will be administered divided over 4 locations. The needle is inserted in-plane from the anterior aspect of the axillary artery and directed toward the posterior aspect of the axillary artery to first anesthetize the radial nerve. The posteriorly located radial nerve is surrounded with 8 mL of local anesthetic. Afterward, the needle is withdrawn and redirected to the median and ulnar nerves, after which another 8 mL of local anesthetic is deposited. In the end, the needle is withdrawn and redirected toward the musculocutaneous nerve where another 4 mL of local anesthetic is deposited.
Study: NCT06009744

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Low-dose vitamin C and zinc
Description: This is a randomized, control trial to investigate the effect of Vitamin C and Zinc in patients with enterocutaneous fistulas receiving nutrition parenteral therapy and Vitamin C 100-300 mg/d and zinc 3-5 mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-dose vitamin C and zinc
Description: This is a randomized, control trial to investigate the effect of Vitamin C and Zinc in patients with enterocutaneous fistulas receiving nutrition parenteral therapy and Vitamin C 1000-2000 mg/d y zinc 10-15 mg/d
Study: NCT06232434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prospidelong
Description: Prospidium chloride (in the form of prospidelong (a mixture of prospidium chloride and dextran sodium salt phosphate containing carbamate groups in a 1:1 ratio)) - 1000 mg.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: chemotherapy
Description: after diagnostic laparotomy/laparoscopy, systemic chemotherapy in accordance with the clinical protocol Algorithms for the diagnosis and treatment of malignant neoplasms (approved by Resolution of the Ministry of Health of the Republic of Belarus No. 60 of 07/06/2018), namely the section regulating the treatment of patients suffering from metastatic gastric cancer with a degree of prevalence tumor process corresponding to sT1-4N0-3M1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: after diagnostic laparotomy/laparoscopy, systemic chemotherapy in accordance with the clinical protocol Algorithms for the diagnosis and treatment of malignant neoplasms (approved by Resolution of the Ministry of Health of the Republic of Belarus No. 60 of 07/06/2018), namely the section regulating the treatment of patients suffering from metastatic gastric cancer with a degree of prevalence tumor process corresponding to sT1-4N0-3M1
Study: NCT05559684

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: Under strict aseptic precautions, The T3 spinous process will be located. A high-frequency 12 MHz linear US transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process. Three muscles; trapezius (uppermost), rhomboids major (middle), and erector spinae (lowermost) will be identified superior to the hyperechoic transverse process. Using in-plane approach a 25 G needle will be inserted in caudal-cephalad direction, until the tip is deep to erector spinae muscle. Correct needle tip location will be confirmed by injecting 3 mL of normal saline and visualizing the linear LA spread (i.e., hydrodissection) in the fascial plane between the erector spinae muscle and the transverse process. Then, 0.4 ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) will be injected and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus thoracis plane block
Description: Under strict aseptic precautions, the T4-T5 intercostal space is identified under US using the US probe in the longitudinal plane 1 cm lateral to the sternal border. A high-frequency linear transducer is used. Next, a parasternal sagittal view of the intercostal muscle and the transverses thoracis muscle between the 4th and 5th rib is visualized above the pleura and a 22G, 5-10 cm needle is inserted in-plane (according to patient's body habitus and relevant anatomy) to the transducer with bevel up until the tip of the needle is located in the transverses thoracis muscles. After excluding intravascular and intrapleural placement, local anesthetic is adminstred bilaterally by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%) at each side.
Study: NCT04765670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: Bilateral Instrument assisted soft tissue mobilization application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape Application
Description: Bilateral Kinesiotape application will be applied in a single session to the trapezius and sternocleideomastoideus muscles.
Study: NCT05271123

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of respiratory function and growth motor function classiffication level
Description: Assessment of respiratory function using spirometer and assessment of growth motor function classiffication level using GMFCs
Study: NCT05879224

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Revised case management package
Description: 1. Point-of-care quantitative G6PD testing using G6PDSTANDARD (SD Biosensor) prior to use of primaquine (Day 0)~2. Prescription of short course primaquine (7 mg/kg total)(Day 0):~   * PQ7 (1 mg/kg/day for 7 days) if G6PD activity greater than 70 percent~  * PQ14 (0.5 mg/kg/day for 14 days) if G6PDactivity is 30-70 percent~  * PQ8w (0.75 mg/kg/week for 8 weeks) if G6DPactivity less than 30 percent~3. Participant counselling at the health facility (Day 0):~   * Supervision of first dose of primaquine~  * Education regarding the importance and risks of primaquine therapy and necessity to take primaquine with food~4. Community based clinical review on Day 3 (and Day 7 for the first 300 participants) to detect and manage gastrointestinal or haemolytic adverse effects of treatment and encourage adherence to full treatment regime~5. Improved malariometric surveillance and pharmacovigilance to support wider scale use of the revised case management
Study: NCT05837702

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESPB
Description: Erector spinae plane block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVB
Description: Paravertebral Block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL
Description: No block has been done
Study: NCT04854083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide, 1.34 mg/mL
Description: The low-calorie diet (LCD) has a phase run-in period for 13 weeks for all participants including 8 weeks of total LCD followed 5-week gradual re-introduction of food (replacement of the VLCD products by one meal/week). During re-introduction of food, the subjects will be randomly assigned to semaglutide 1.34mg/ml (subcutaneous administration, dose escalation 0.25 mg once weekly for 4 weeks, 0.5 mg once weekly for 4 weeks, where after 1.0 mg once weekly) until the end of the study (12 months). The participants will receive lifestyle counselling throughout the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The low-calorie diet (LCD) has a phase run-in period for 13 weeks for all participants including 8 weeks of total LCD followed 5-week gradual re-introduction of food (replacement of the VLCD products by one meal/week). During re-introduction of food, the subjects will be randomly assigned to placebo (subcutaneous administration, dose escalation 0.25 mg once weekly for 4 weeks, 0.5 mg once weekly for 4 weeks, where after 1.0 mg once weekly) until the end of the study (12 months). The participants will receive lifestyle counselling throughout the study.
Study: NCT05400252

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Omnis Salutis
Description: Omnis Salutis is a Veteran-targeted, Whole Health program for mental health care settings and teaches Veterans the skills to identify and communicate their Whole Health goals to providers and social supports

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and Wellness
Description: Health \& Wellness is an educational wellness intervention
Study: NCT05416411

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inspiratory muscle training
Description: Patients will do inspiratory muscle training via a flow resistive device. Priorly, maximum inspiratory pressure will be measured. Afterwards, the training device will be set to 10% increased value of maximum inspiratory pressure (MIP), and the training will be completed two times and 30 repetitions a day during preoperative 7 days. Meanwhile patients will be advised to walk 5000 steps a day during the intervention period.
Study: NCT06499688

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rcombinant botulinum neurotoxin type A for injection (YY001)
Description: Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single treatment,intramuscularly injected into five sites.The total injection volume is 0.25 ml,0.05 ml per site.